ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

As well as the IPF candidate, the merger gave Aileron a phase-2b-ready treatment for loculated pleural effusions and a cystic fibrosis program. Finding funding for the programs remains an issue.

Rein also provided an update on its pipeline, highlighting LTI-01, a Phase 2b-ready therapy for loculated pleural effusions, which holds Orphan Drug Designation for pleural empyema. Brian Windsor ...

LTI-01: The Company’s Phase 2b-ready asset is a first-in-class therapy for the treatment of loculated pleural effusions. It holds Orphan Drug Designation for the treatment of pleural empyema in ...